[{"orgOrder":0,"company":"Cardinal Health","sponsor":"Clarity Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Peptide","year":"2021","type":"Agreement","leadProduct":"67-Cu MeCOSar-Tyr3-octreotate","moa":"SST2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cardinal Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cardinal Health \/ Cardinal Health","highestDevelopmentStatusID":"7","companyTruncated":"Cardinal Health \/ Cardinal Health"},{"orgOrder":0,"company":"Cardinal Health","sponsor":"Carisma Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"Vicineum","moa":"Epithelial cell adhesion molecule","graph1":"Oncology","graph2":"Phase III","graph3":"Cardinal Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cardinal Health \/ Sesen Bio","highestDevelopmentStatusID":"10","companyTruncated":"Cardinal Health \/ Sesen Bio"},{"orgOrder":0,"company":"Cardinal Health","sponsor":"Cardinal Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Cardinal Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cardinal Health \/ Cardinal Health","highestDevelopmentStatusID":"8","companyTruncated":"Cardinal Health \/ Cardinal Health"}]

Find Clinical Drug Pipeline Developments & Deals by Cardinal Health

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          April 05, 2023

                          Lead Product(s) : Cisplatin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : Fox Chase Cancer Center

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Cardinal Health will provide cGMP product manufacturing of ready-to-use TCT for Clarity’s U.S.-based clinical trials from its Center for Theranostics Advancement. TCT are radiopharmaceuticals that pair copper-64 (64Cu) and copper-67 (67Cu) for diagnosi...

                          Product Name : Undisclosed

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          February 12, 2021

                          Lead Product(s) : 67-Cu MeCOSar-Tyr3-octreotate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Recipient : Clarity Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          03

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Cardinal Health will provide comprehensive end-to-end 3PL to Sesen Bio in support of commercialization in the U.S. The Company’s lead program, Vicineum is currently in the follow-up stage of a Phase 3 registration trial for the treatment of high-risk, ...

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Undisclosed

                          October 19, 2020

                          Lead Product(s) : Vicineum

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Carisma Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Radiolabeled Compounds

                          Upfront Cash : Inapplicable

                          August 05, 2016

                          Lead Product(s) : 99m-Tc Tilmanocept

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 11, 2015

                          Lead Product(s) : Loxoprofen Sodium

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase II

                          Recipient : Lead Chemical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Lead Product(s) : 99m-Tc Tilmanocept

                          Therapeutic Area : Oncology

                          Study Phase : Phase I

                          Recipient : University of California, San Diego

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Radiolabeled Compounds

                          Upfront Cash : Inapplicable

                          October 28, 2015

                          Lead Product(s) : 99m-Tc Tilmanocept

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : University of California, San Diego

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Radiolabeled Compounds

                          Upfront Cash : Inapplicable

                          July 28, 2015

                          Lead Product(s) : 99m-Tc Tilmanocept

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Radiolabeled Compounds

                          Upfront Cash : Inapplicable

                          July 28, 2015

                          Lead Product(s) : 99m-Tc Tilmanocept

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank